Study design and participants
This was a large-scale, multicenter retrospective observational study including patients with IAs who were admitted to one of the study hospitals between May 1, 2013 and June 30, 2018. The study was approved by the ethics committees of Seirei Hamamatsu General Hospital and all other participating institutions. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (registration no: UMIN000010404).
In the present study, UIA was defined as an unruptured saccular aneurysm, ≥ 3 mm in largest diameter, in the subarachnoid space. Even if one of UIAs ruptured, it was classified as an RIA The diagnosis of UIA and RIA was made by board-certified neurosurgeons or neuroradiologists. The largest aneurysm diameter was measured on images captured using ≥ 1.5-T magnetic resonance images without contrast media or computed tomography angiography with contrast media. The exclusion criteria were antibiotic use within 2 months before the collection of saliva specimens, IA due to bacterial endocarditis, and dissecting IAs. Patients without teeth were also excluded because SM can be cultured only from the oral cavity with at least one tooth19,20.
Among a total of 992 patients who were admitted to one of the study institutions during the study period, 91 patients, including 59 patients without teeth, 34 patients with antibiotic usage within 2 months, 22 patients with extradural aneurysms, and 4 patients with dissecting aneurysms, were excluded. Therefore, the final study cohort included 901 patients with at least one IA, including 431 patients with RIAs and 470 patients with UIAs.
In the present study, data were collected on age, sex, smoking and drinking habits, family history of subarachnoid hemorrhage, number of teeth, and known risk factors, including hypertension, diabetes mellitus (DM), hyperlipidemia, and chronic kidney disease (CKD).
Definitions of known risk factors
In the present study, hypertension in inpatients was defined as (i) the use of antihypertensive medications before stroke or at discharge or (ii) systolic blood pressure (sBP) ≥ 140 mmHg or diastolic blood pressure (dBP) ≥ 90 mmHg at every measurement during the week before discharge. In outpatients, hypertension was defined as (i) the use of antihypertensive medications, (ii) sBP ≥ 140 mmHg or dBP ≥ 90 mmHg at all visits within 3 months, or (iii) home-measured sBP ≥ 140 mmHg or dBP ≥ 90 mmHg at all measurements.
DM in inpatients was defined as the use of oral hypoglycemic agents or insulin before stroke or at discharge or a fasting blood glucose level ≥ 6.99 mmol/L (126 mg/dL) measured during the week before discharge. DM in outpatients was defined as the use of oral hypoglycemic agents or insulin or a fasting blood glucose level ≥ 6.99 mmol/L (126 mg/dL) measured in the last 3 months.
In all patients, hyperlipidemia was defined as fasting or nonfasting total plasma cholesterol ≥ 5.7 mmol/L (220 mg/dL) or low-density lipoprotein cholesterol ≥ 3.63 mmol/L (140 mg/dL) at admission.
CKD was defined as proteinuria during the 3 months before admission, decline in renal function defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2 during the 3 months before admission, or self-reported CDK.
Smoking was defined as current smoking, and alcohol use was defined as consumption of > 150 gram of alcoholethanol per week.
Definition of Cnm-positive SM
To determine the presence of SM in patients, whole saliva samples were collected using a sterile cotton swab (Seed Swab no. 2; Eiken Chemical, Tokyo, Japan). Samples from patients with RIAs were collected immediately after admission and before the initiation of prophylactic antibiotics. In patients with UIAs, samples were also collected before the use of antibiotics. The collected samples were immediately frozen and cultured within 3 weeks of collection.
For SM cultures, the saliva samples were streaked onto mitis Salivarius Agar plates (Difco Laboratories, Detroit, MI, USA) containing bacitracin (0.2 U/mL; Sigma-Aldrich, St. Louis, MO, USA) and 15% (w/v) sucrose and were anaerobically cultured at 37°C for 48 h. After identifying the characteristic SM, colony morphology, five colonies were picked for each patient sample and further cultured in brain heart infusion broth (Difco Laboratories) at 37°C for 18 h21.
The presence of SM was confirmed in all colonies using polymerase chain reaction with TaKaRa Ex Taq polymerase (Takara, Otsu, Japan) and the following primer pair: MKD-F, GGC ACC ACA ACA TTG GGA AGC TCA GTT; MKD-R, GGA ATG GCC GCT AAG TCA ACA GGA T22. Additionally, the detection of cnm was performed using polymerase chain reaction with TaKaRa Ex Taq polymerase and the following primer pair: Cnm-1F, GAC AAA GAA ATG AAA GAT GT; Cnm-1R, GCA AAG ACT CTT GTC CCT GC21.
Study outcomes
In the present study, we evaluated four outcomes. First, we evaluated the risk factors for rupture in all IA cases. Second, we determined whether the positive rate of Cnm-positive SM was different between the patients with RIAs and UIAs. Third, we determined whether the rate of Cnm-positive SM differed on the basis of IA size. To that end, we categorized IAs into those with diameters of < 5, ≥5 and < 10, and ≥ 10 mm. Finally, we compared the rate of Cnm-positive SM between the patients with UIAs and RIAs based on an IA size of < 10 mm versus ≥ 10 mm.
Statistical analysis
We used the χ2 and the Cochran–Mantel–Haenszel tests to compare binary variables and the Mann–Whitney U test to compare continuous variables. Statistical significance was defined as a P value of < 0.05. Logistic regression analysis with corresponding odds ratios and 95% confidence intervals were used to adjust covariates. In our previous study including healthy volunteers8, the rate of positivity for Cnm-positive SM was 43.5% in patients with RIAs and 14.9% in healthy volunteers. In the present study including patients with UIAs as controls, we assumed that the rate of positivity for Cnm-positive SM in patients would be twice of that for healthy volunteers5, which would mean a difference of 10% using the χ2 test with α and β error levels of 0.05 and 0.2, respectively23. The ratio of patients with RIAs to those with UIAs would be 1:1; therefore, the total sample size was calculated as 742 patients with a two-tailed test. Assuming a dropout rate of 20%, a target of 891 patients was set for the present study. All statistical analyses were performed using SAS University Edition (SAS Institute, Cary, NC, USA).
Trial Registry
University Hospital Medical Information Network Clinical Trials Registry (registration no: UMIN000010404; https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012168)